Adherium Limited has raised $1.6 million in new investment capital from investors. The Global Respiratory eHealth company focuses on patient medication adherence, remote monitoring, and data management solutions tailored for patients, payers, and providers. Adherium's flagship offering, the HailieĀ® sensor technology and cloud-based data platform, provides real-time feedback on patients' use of inhaled medication. This innovative technology is specifically designed to enable optimal management of difficult-to-treat and severe asthma and COPD, with the overarching goal of reducing direct and indirect healthcare costs.
The company's HailieĀ® digital solution comprises patented sensors and proprietary algorithms that precisely track medication delivery, capturing essential data for clinicians and generating auditable reimbursement reports for payers and providers. Adherium emphasizes its robust clinical evidence, citing over 85 studies involving 13,000 patients, which demonstrate its proven effectiveness in improving adherence and patient outcomes. With over 170,000 devices sold across 30 countries and the widest US inhaler market coverage, the company has established a significant footprint in the digital respiratory health space.
This funding round is significant for Adherium as it seeks to capitalize on the growing demand for digital health solutions and the positive reimbursement environment for remote patient monitoring (RPM). The newly secured capital will primarily support ongoing technology upgrades, specifically those aimed at accessing US reimbursement opportunities and further expanding its market presence. Adherium plans to strategically deploy these funds for key growth initiatives, including the continued development of its solutions and the strengthening of its strategic partnerships. This investment positions Adherium to further advance its mission of improving patient outcomes and delivering substantial value within the evolving respiratory eHealth sector.
